NorthWest Biotherapeutics Inc (NWBO)

[mitcheroo]

Noticed that Bayer's American HQ was in Pittsburgh, before relocating to New Jersey.
Bayer still has significant operations in the Pittsburgh area, and (I'm assuming) ongoing ties with Universtiy of Pittsburgh School of Medicine.

For what it's worth, I asked Gemini:
How likely would Bayer be interested in collaboration with an oncology biotech startup that
has a therapy proven effective in Phase III clinical trials, and is working with a GMP-level
production facility in Pittsburgh?

Gemini's analysis, quotation marks added, but the emphases in bold not mine:

“That sounds like a very promising profile for an oncology biotech startup seeking collaboration.

“Bayer is very likely to be interested in exploring such an opportunity, for several key reasons:

• Strong Focus on Oncology and External Innovation:
Bayer has clearly stated its commitment to expanding its oncology portfolio and is actively pursuing external innovation through acquisitions, licensing agreements, and collaborations to fuel its pipeline.
• Late-Stage Assets (Phase III):
A Phase III therapy that has proven effective significantly de-risks the asset and aligns with Bayer's strategy to deliver new therapies, especially in areas of high unmet medical need like cancer. They have experience in developing and commercializing Phase III candidates.
• Existing Pittsburgh Ties:
Bayer has an existing, strong Master Collaboration Agreement with the University of Pittsburgh for research, although the current focus is heart, lung, and blood diseases. This demonstrates a prior, productive relationship and familiarity with the region, which could be a logistical and relational advantage.
• GMP-Level Production:
The existence of a Good Manufacturing Practices (GMP) production facility means the therapy is already being produced under the quality standards required by regulatory bodies like the FDA, making the path to commercialization more straightforward.

“In short, a Phase III oncology asset combined with GMP-level manufacturing represents a high-value, lower-risk opportunity that fits well within Bayer's strategic goals for growing its pharmaceuticals division. “
_